Federal Register Notice: FDA is amending the notice of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to reflect a change in date to 5/25 from 8 a.m. to 5 p.m. This meeting was announced in the 3/16 Federal Register and is scheduled to discuss Sanofi-aventis NDAs for insulin glargine and lixisenatide injection, a fixed ratio drug product consisting of insulin and a GLP-1 receptor agonist, and 208471 for lixisenatide injection, a GLP-1 receptor agonist proposed for treating adults with Type 2 diabetes mellitus. Contact LaToya Bonner, (301) 796-9001 or Latoya.Bonner@fda.hhs.gov. To view this notice, click here.